Summary

Oxytocin is a nine-amino-acid neuropeptide hormone produced in the hypothalamus, widely studied for its roles in social bonding, stress regulation, reproductive physiology, and emerging metabolic research. Synthetic oxytocin is a Prescription-Only Medicine (POM) in the UK when used for medical purposes.

Mechanism

Oxytocin acts through the oxytocin receptor (OXTR), a G-protein-coupled receptor expressed in the brain (amygdala, hippocampus, nucleus accumbens, hypothalamus) and peripheral tissues (uterus, mammary gland, heart, adipose tissue). Central effects on social behaviour are mediated through limbic and prefrontal circuits. Peripheral metabolic effects may involve direct action on adipose tissue and gut-brain signalling via the vagus nerve. Oxytocin also modulates the HPA axis, reducing CRF and ACTH release in stress contexts.

Evidence base

Evidence Grading: Moderate

Human clinical data: Hundreds of intranasal oxytocin studies, including multiple RCTs and meta-analyses, support effects on social cognition and stress modulation. Emerging metabolic research (2–3 small RCTs) shows appetite-reducing and modest weight-loss effects.

Limitations: Effect sizes for social behavioural effects are small. Publication bias has been documented. Metabolic studies have small sample sizes (n<50). Long-term safety data for chronic intranasal administration is limited. Intranasal delivery results in variable and poorly characterised brain bioavailability.

Key gap: Large-scale Phase 3 trials for obesity or neuropsychiatric indications are lacking.

Protocols

Published research most commonly uses intranasal oxytocin at 24–40 IU per dose, administered in divided doses (e.g., 24 IU four times daily in the Lawson et al. metabolic trial). Single-dose studies of 24 IU intranasally are typical for social cognition research. Subcutaneous protocols at 0.5–2 IU have been discussed in research contexts but are less well-studied than intranasal routes.

Oxytocin is a Prescription-Only Medicine (POM) in the UK, licensed for obstetric use. Supply without a prescription is an offence under the Human Medicines Regulations 2012. Research-grade oxytocin sold as a research chemical occupies a regulatory grey area, but MHRA enforcement targets products marketed for human consumption. The MHRA's 2026 guidance on research peptide labelling further clarified these requirements.

Vendor notes

Oxytocin for obstetric use is available by prescription only (Syntocinon). Research-grade oxytocin may be available from some UK research chemical suppliers. Researchers should verify supplier COAs. See the vendor vetting guide for evaluation criteria.

References

  1. Bakermans-Kranenburg MJ, van IJzendoorn MH. A sniff of trust: meta-analysis of the effects of intranasal oxytocin administration on face recognition, trust to in-group, and trust to out-group. Psychoneuroendocrinology. 2013;38(4):508-516.
  2. Heinrichs M, et al. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biological Psychiatry. 2003;54(12):1389-1398.
  3. Lawson EA, et al. Oxytocin reduces caloric intake in men. Obesity. 2015;23(5):950-956.
  4. Thienel M, et al. Oxytocin's inhibitory effect on food intake under conditions of homeostatic as opposed to hedonic eating. Biological Psychiatry. 2019;85(9):771-779.
  5. Du Vigneaud V, et al. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. Journal of the American Chemical Society. 1953;75(19):4879-4880.